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ersus Amlodipine on Left Ventricular
ass and Reactive Oxygen Species
ormation by Monocytes in Hypertensive
atients With Left Ventricular Hypertrophy
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OBJECTIVES To compare the effects of the angiotensin receptor blocker (ARB) valsartan versus the calcium
channel blocker amlodipine, reactive oxygen species (ROS) formation by monocytes,
C-reactive protein (CRP), and left ventricular (LV) mass were studied in 104 hypertensive
patients with left ventricular hypertrophy (LVH).
BACKGROUND There is evidence that ARBs have blood pressure (BP)-independent effects on LV mass.
Whether regression of LV mass by ARBs is correlated to ROS formation by monocytes and
CRP is not fully understood yet.
METHODS A cross-sectional and prospective study was performed. Participants were randomly assigned
to either the 80-mg valsartan (n  52) or 5-mg amlodipine (n  52) group and were treated
for eight months. The left ventricular mass index (LVMI) was calculated from two-
dimensional M-mode echocardiography. Formation of ROS by monocytes was measured by
gated flow cytometry. In addition, CRP, plasma renin activity, plasma aldosterone, and
traditional risk factors were assessed.
RESULTS Multiple regression analysis showed a significant correlation between LVMI and ROS
formation by monocytes and between LVMI and CRP. Treatment reduced BP to a similar
extent in both groups. Valsartan significantly reduced LVMI after eight months, but
amlodipine had less effect (16% vs. 1.2%, n  50, p  0.01). Formation of ROS by monocytes
was reduced to a greater extent with valsartan than with amlodipine (28% vs. 2%, n  50, p
 0.01). Valsartan but not amlodipine reduced CRP levels. A significant correlation between
changes in ROS formation by monocytes and LVMI or between CRP and LVMI was
observed.
CONCLUSIONS The ARB valsartan has BP-independent effects on LVH, ROS formation by monocytes, and
CRP in hypertensive patients with LVH. (J Am Coll Cardiol 2004;43:2116–23) © 2004 by
the American College of Cardiology Foundation(
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aeft ventricular hypertrophy (LVH), the most common
ardiac consequence of hypertension, is a strong risk factor
or cardiovascular complications and morbidity (1,2). In
ddition to pressure load, LVH appears to be modified by
enetic and humoral factors (3,4). Among the most impor-
ant of such factors is the renin-angiotensin system (5,6).
ngiotensin II (ATII) is a powerful stimulator of myocyte
rowth, and many studies have shown the relationship
etween plasma ATII and LVH in essential hypertension
7,8).
There is evidence for increased inflammation in some
atients with essential hypertension. Evidence for increased
nflammation includes increased reactive oxygen species
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Manuscript received October 1, 2003; revised manuscript received December 9, 2003,nccepted December 15, 2003.ROS) formation by monocytes (9) and increased levels of
lasma C-reactive protein (CRP) (10). Increased intracel-
ular ROS formation by monocytes can lead to increased
xpression of cell surface adhesion molecules, which are
egarded as markers of inflammation (11). Recently, we
emonstrated the relationship between CRP and ROS
ormation by monocytes (12). It has been reported that
RP stimulates interleukin (IL)-6 release from monocytes
13) and that continuous activation of the IL-6 receptor
nduces myocardial hypertrophy in mice (14).
Angiotensin receptor blockers (ARBs) are a well-
stablished form of antihypertensive therapy and have re-
ently been shown to have benefits beyond blood pressure
BP) reduction—for example, in microalbuminuria in dia-
etic subjects (15). In the Losartan Intervention For End-
oint reduction (LIFE) trial (16), the ARB losartan had
reater effects on LVH than the comparator substance
tenolol for the same reduction in BP. To our knowledge,
o study has investigated the possible involvement of
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June 2, 2004:2116–23 Monocytes and LV Massnflammatory markers such as ROS formation by mono-
ytes or CRP in an ATII-mediated increase in LV mass.
In the present study, we compared the changes in LVH
nd the changes in inflammatory markers such as monocyte
OS formation and levels of CRP caused by treatment with
he ARB valsartan or the calcium channel blocker amlodip-
ne. The possible involvement of inflammatory markers in
n ATII-mediated increase in LV mass in hypertensive
atients was also studied.
ETHODS
articipants. This study consisted of two phases: a cross-
ectional analysis of the relationship between the left ven-
ricular mass index (LVMI) and risk of LVH, as well as a
rospective, randomized, double-blinded study of hyperten-
ive subjects with LVH who visited Osaka City University
ospital from April 1999 to April 2002. The primary
utcome was the change in LVH associated with treatment,
nd the secondary outcome was the change in inflammatory
arkers such as oxidative stress in monocytes and CRP
ssociated with treatment. The relationship between LVH
nd inflammatory markers was also studied.
Table 1. Baseline Characteristics of Hypertens
Age (yrs)
Gender (M/F)
Body mass index (kg/m2)
Systolic BP (mm Hg)
Diastolic BP (mm Hg)
ROS formation by monocytes (arbitrary units)
C-reactive protein (mg/dl)
LVMI (g/m2)
Glycosylated hemoglobin (%)
Triglyceride (mg/dl)
HDL cholesterol (mg/dl)
LDL cholesterol (mg/dl)
Renin (ng/ml/h)
Aldosterone (pg/ml)
*Computed with the Mann-Whitney U test. Data are presente
as the median value (interquartile range).
BP  blood pressure; HDL and LDL  high- and low-de
Abbreviations and Acronyms
ARB  angiotensin receptor blocker
ATII  angiotensin II
BP  blood pressure
CDCFH bis-AM ester  carboxydichlorofluorescein
diacetate bis-acetoxymethyl
ester
CRP  C-reactive protein
IL  interleukin
LV  left ventricular
LVH  left ventricular hypertrophy
LVMI  left ventricular mass index
ROS  reactive oxygen speciesROS  reactive oxygen species.Subjects who had not been treated for hypertension or who
ad discontinued antihypertensive agents and who had a BP of
140/90 mm Hg after a double-blinded, four-week placebo
un-in period were included in the trial. During the run-in
eriod, the presence of LVH was established by echocardiog-
aphy and defined as LVMI 134 g/m2 for men and 110
/m2 for women and/or septal thickness 12 mm at end
iastole (17). None of the subjects were taking any medica-
ions, including nonsteroidal anti-inflammatory drugs, vitamin
, or other antioxidants. Randomization was performed by a
ontroller who did not know the results and was using a
omputer-generated random allocation sequence in a num-
ered container. The subjects were given oral 80 mg of
alsartan or the calcium channel blocker amlodipine (5 mg) for
ight months. The protocol was approved by the Institutional
eview Board of Osaka City University. Written, informed
onsent was obtained from all subjects.
Systolic and diastolic BPs were recorded as the average of
he second and third rest period, seated, cuff BP measure-
ents, in systole and diastole, respectively, measured after a
-min rest period. Fasting blood samples were collected,
nd echocardiography was performed at baseline and at
onth 8. Obesity was estimated in terms of body mass
ndex. Plasma insulin, plasma glucose, glycosylated hemo-
lobin, plasma cholesterol, triglyceride, high-density li-
oprotein cholesterol, plasma renin and aldosterone concen-
rations were measured in venous blood. Serum CRP was
easured by latex-enhanced immunonephelometric assay
n a BN II analyzer (Dade Behring, Newark, Delaware), a
ighly sensitive technique.
ssay of ROS formation by monocytes. Formation of
OS by monocytes was measured using a gated flow
ytometric technique, as described in previous studies
18,19), with some modifications (11). Fresh blood (1 ml)
as collected from participants into preservative-free hepa-
in (10 U/ml blood). The blood was pre-incubated for 15
atients
alsartan
roup
 52)
Amlodipine
Group
(n  52) p Value*
2  11 64  12 0.6
31/21 31/21 1.0
1  3.8 24.3  2.8 0.8
2  8 152  6 1.0
3  5 92  6 0.4
1  20 86  24 0.3
0.10–0.30) 0.10 (0.05–0.20) 1.0
6  29 161  39 0.5
4  0.5 5.4  1.0 1.0
3  59 127  85 0.3
3  13 54  13 0.7
8  26 114  34 0.5
7  2.25 1.83  3.45 0.8
1  3.9 11.7  7.7 0.2
e mean value  SD, except for C-reactive protein, expressed
ipoprotein, respectively; LVMI  left ventricular mass index;ive P
V
G
(n
6
24.
15
9
9
0.10 (
16
5.
11
5
11
1.6
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Monocytes and LV Mass June 2, 2004:2116–23in with 2,7-carboxydichlorofluorescein diacetate bis-
cetoxymethyl ester (CDCFH bis-AM ester) (100 mol/l)
n a 37°C water bath with gentle horizontal shaking. The
DCFH bis-AM ester is a nonpolar compound that is
onverted into a nonfluorescent polar derivative (CDCFH)
y cellular esterases after incorporation into cells. CDCFH
s membrane-impermeable and rapidly oxidized to the
ighly fluorescent carboxydichlorofluorescein in the pres-
nce of intracellular hydrogen peroxide and peroxidase. Red
lood cells were lysed, and white blood cells were suspended
n 1% paraformaldehyde/phosphate-buffered saline. The
xed samples were kept on ice until flow cytometric analysis
n the same day. Formation of ROS by monocytes was
easured as the fluorescence intensity by gated flow cytom-
try. The coefficients of variation of the intra- and inter-
ssays were 6.6% and 10.2%, respectively.
Table 2. Multiple Regression Analysis of the R
and Other Variables for the Entire Group
Variables
R
C
Age (yrs)
Gender (female)
Body mass index (kg/m2)
Systolic BP (mm Hg)
Diastolic BP (mm Hg)
Glycosylated hemoglobin (%)
Triglycerides (mg/dl)
HDL cholesterol (mg/dl)
LDL cholesterol (mg/dl)
C-reactive protein (mg/dl)
ROS formation by monocytes (arbitrary units)
Renin (ng/ml/h)
Aldosterone (pg/ml)
The dependent variable is left ventricular mass index. In
glycosylated hemoglobin triglycerides, HDL cholesterol, LD
renin, and aldosterone.
Abbreviations as in Table 1.
igure 1. Relationships between reactive oxygen species (ROS) formation
-reactive protein (CRP) and LVMI (n  104).chocardiography. Two-dimensional directed and
uided M-mode echocardiographic studies were per-
ormed in all participants by one experienced investiga-
or. The investigator reading the echocardiograms was
linded as to the treatment group. The LV mass was
easured on the M-mode guided echocardiogram, ac-
ording to the method recommended by the American
ociety of Echocardiography (20). Left ventricular mass
as derived from the formula described by Devereux et
l. (17):
LV mass (g)  0.80  1.04 VSTd LVIDd PWTd]3
 [LVIDd]3  0.6
here VSTd is the end-diastolic ventricular septal thick-
ess; LVIDd is the LV end-diastolic internal dimension;
nd PWTd is the LV end-diastolic posterior wall thickness.
onship Between Left Ventricular Mass Index
ssion
cient
Standard
Error
Standardized
Regression
Coefficient p Value
12 0.31 	0.04 0.70
42 6.96 	0.12 0.23
39 1.03 0.23 0.02
01 0.48 0.21 0.04
67 0.60 	0.11 0.26
45 4.17 	0.15 0.13
03 0.05 	0.06 0.54
18 0.29 	0.07 0.55
03 0.11 	0.02 0.83
71 10.23 0.20 0.04
45 0.15 0.29 0.01
17 1.12 0.19 0.06
33 0.58 	0.06 0.57
ent variables are age, gender, systolic BP, diastolic BP,
lesterol, C-reactive protein, ROS formation by monocytes,
onocytes (MNCs) and left ventricular mass index (LVMI) and betweenelati
egre
oeffi
	0.
	8.
2.
1.
	0.
	6.
	0.
	0.
	0.
21.
0.
2.
	0.
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June 2, 2004:2116–23 Monocytes and LV Masstatistical analysis. All data are expressed as the mean
alue  SD, unless otherwise specified. Statistical analyses
ere performed using Statview 5.0 and JMP 4.0 (SAS
nstitute, Cary, North Carolina). Statistical analysis of the
esults for intergroup comparisons was performed with the
tudent t test preceded by an F test. A comparison of
easurements at baseline and six months later was carried
ut by the paired t test (two-sided p value and 95%
onfidence interval [CI]). C-reactive protein was expressed
s the median value (interquartile range), and p values were
omputed by the Mann-Whitney U test for intergroup
omparisons at baseline. The relationship between LVMI
able 3. Changes in Measurements From Baseline to Six Month
Valsartan Group (n  50)
Difference 95% CI
p
(In
ody mass index (kg/m2) 0.2 (0 to 0.3)
ystolic BP (mm Hg) 	12 (	14 to 	10)
iastolic BP (mm Hg) 	7 (	8 to 	6)
onocyte oxidative stress
(arbitrary units)
	26 (	31 to 	21)
-reactive protein (mg/dl) 	0.14 (	0.22 to 	0.07)
VMI (g/m2) 	28 (	35 to 	21)
lycosylated hemoglobin (%) 0 (	0.1 to 0.1)
riglycerides (mg/dl) 1 (	11 to 12)
DL cholesterol (mg/dl) 	1 (	3 to 1)
DL cholesterol (mg/dl) 	2 (	8 to 4)
enin (ng/ml/h) 0.4 (	0.1 to 1.0)
ldosterone (pg/ml) 	0.5 (	1.5 to 0.5)
I  confidence interval; other abbreviations as in Table 1.
igure 2. Effect of valsartan (n  50) and amlodipine (n  50) on left ve
he mean value  SD. p  0.01 for baseline versus six months later in the
roup.nd relevant covariates was examined by determination of
tandardized correlation coefficients and linear regression
nalysis.
ESULTS
aseline characteristics. During the four-week run-in pe-
iod, among the 120 patients who underwent randomiza-
ion, 16 participants withdrew because they became normo-
ensive. Two patients in each treatment group discontinued
he study because of adverse events. In the valsartan group,
iver dysfunction (n  1) and headache (n  1) were
Amlodipine Group (n  50)
p Value
(Intergroup)
e
up) Difference 95% CI
p Value
(Intragroup)
0.2 (0 to 0.5) 0.1 1.00
1 	11 (	13 to 	9) 0.01 0.48
1 	8 (	10 to 	5) 0.01 0.52
1 	7 (	15 to 2) 0.1 0.01
1 0.01 (	0.04 to 0.06) 0.9 0.01
1 	3 (	7 to 1) 0.1 0.01
0.1 (0 to 0.2) 0.3 0.16
	10 (	29 to 10) 0.3 0.27
	1 (	3 to 1) 0.2 1.00
	5 (	10 to 1) 0.1 0.48
0 (	0.7 to 0.7) 0.9 0.19
	1 (	2.6 to 0.6) 0.2 0.59
lar mass index (LVMI). The open circles on the vertical bars represent
tan group; p  0.01 for baseline versus six months later in the amlodipines
Valu
tragro
0.4
0.0
0.0
0.0
0.0
0.0
1.0
0.9
0.2
0.5
0.1
0.3ntricu
valsar
o
p
i
i
c
v
q
T
o

b
L
p
r
L
F
C
r
F
t
l
F
m
2120 Yasunari et al. JACC Vol. 43, No. 11, 2004
Monocytes and LV Mass June 2, 2004:2116–23bserved. In the amlodipine group, tachycardia (n  1) and
retibial edema (n  1) were observed.
Baseline characteristics in each treatment group are shown
n Table 1. Subjects were well matched for age, body mass
ndex, BP, gender, glycosylated hemoglobin, triglycerides, and
holesterol. There were no significant differences between the
alues for LVMI, CRP, and ROS formation by monocytes.
At baseline, multiple regression analysis was used to
uantify the correlation of measured variables to LVMI.
he results of the analysis are shown in Table 2. Formation
igure 3. Effect of valsartan (n  50) and amlodipine (n  50) on reactive
he vertical bars represent the mean  SD. p  0.01 for baseline versus
ater in the amlodipine group.
igure 4. Relationships between the decrease (
) in reactive oxygen specie
ass index (LVMI) and between the decrease in C-reactive protein (CRP) andf ROS by monocytes was significantly related to LVMI (r
0.29, p  0.01), and there was a significant correlation
etween CRP, systolic BP, and body mass index with
VMI (for CRP: r  0.20, p  0.04; systolic BP: r  0.21,
 0.04; body mass index: r  0.23, p  0.02). The
elationships between oxidative stress in monocytes and
VMI and between CRP and LVMI are also shown in
igure 1.
hanges in BP. Both valsartan and amlodipine treatment
educed BP to a similar extent. In the valsartan group,
en species (ROS) formation by monocytes (MNCs). The open circles on
onths later in the valsartan group; p  0.1 for baseline versus six months
S) formation by monocytes (MNCs) and the decrease in left ventricularoxyg
six ms (RO
the decrease in LVMI in the valsartan-treated group (n  50).
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June 2, 2004:2116–23 Monocytes and LV Massystolic BP fell from 152  8 mm Hg to 140 7 mm Hg
nd diastolic BP fell from 93  5 mm Hg to 86  5 mm
g. The reductions in the amlodipine group were from 152
6 mm Hg to 140  6 mm Hg for systolic BP and from
2  6 mm Hg to 84  5 mm Hg for diastolic BP. At the
nd of the study, no intergroup difference in systolic and
iastolic BP was observed (Table 3).
VMI. Despite the very similar effects on BP, there were
ighly significant differences between valsartan and amlo-
ipine treatment on LVMI (Table 1, Fig. 2). In the
alsartan group, LVMI decreased from 166  29 g/m2 to
37  26 g/m2, representing a mean decrease of 16  13%
p  0.01) (Fig. 3, Table 3). In contrast, amlodipine had a
esser effect on LVMI, which was reduced from 161  39
/m2 to 158  37 g/m2, a mean decrease of 1.2  8.1% (p
0.14) (Fig. 3, Table 3). The greater reduction in LVMI
ith valsartan compared with amlodipine was statistically
ignificant (p  0.01) (Table 3).
ormation of ROS by monocytes. As with LVMI, there
ere marked differences between the effects of the two
reatments on ROS formation by monocytes. In the valsar-
an group, ROS formation by monocytes was reduced from
1  20 to 65  18 arbitrary units, representing a mean
ecrease of 28  16% (n  50, p  0.01) (Fig. 3, Table 3).
n the amlodipine group, ROS formation by monocytes was
educed from 86  24 to 80  25 arbitrary units, a mean
ecrease of 2  39% (n  50, p  0.11) (Fig. 3, Table 3).
he greater reduction in ROS formation by monocytes with
alsartan compared with amlodipine was statistically signif-
igure 5. Effect of valsartan (n  50) and amlodipine (n  50) on C-reacti
SD. p  0.01 for baseline versus six months later in the valsartan groucant (p  0.01) (Table 3). Linear regression analysis bhowed a significant correlation between the decrease in
VMI and the decrease in ROS formation by monocytes in
he valsartan group (r  0.61, p  0.01) (Fig. 4), but not in
he amlodipine group (r  0.54, p  0.59).
RP. In the valsartan group, CRP levels were reduced
ignificantly, from 0.10 (95% CI 0.10 to 0.30) to 0.08 (95%
I 0.05 to 0.10) mg/dl, a mean decrease of 39  26% (p 
.01) (Fig. 5, Table 3). In contrast, there were no reductions
n CRP levels in the amlodipine group (baseline: 0.10 mg/dl
95% CI 0.05 to 0.20]; month 8: 0.05 mg/dl [95% CI 0.05
o 0.20]; p  0.94) (Fig. 5, Table 3). There was a significant
orrelation between the decrease in CRP and the decrease in
VMI in the valsartan group (r  0.46, p  0.01) (Fig. 4),
ut not in the amlodipine group (r  0.54, p  0.89). The
reater reduction in CRP with valsartan compared with
mlodipine was statistically significant (p  0.01) (Table 3).
n the valsartan group, there was also a significant correla-
ion between the reduction in CRP and the decrease in
OS formation by monocytes (r  0.38, p  0.01), but no
uch correlation was observed in the amlodipine group (r 
.54, p  0.62).
ther traditional risk factors. We also examined the
reatment-induced changes in other traditional risks factors,
uch as age, gender, body mass index, glycosylated hemo-
lobin, triglycerides, and high- and low-density lipoprotein
holesterol, which were measured at baseline and month 8
n both treatment groups. There were no differences in the
aseline levels of these factors between the two groups
Table 1). None of these variables was affected significantly
tein levels. The open circles on the vertical bars represent the mean value
0.7 for baseline versus six months later in the amlodipine group.ve proy treatment (Table 3).
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Monocytes and LV Mass June 2, 2004:2116–23ISCUSSION
ummary of results. This study shows that significant
ifferences exist between the effects of ARB with valsartan
nd calcium channel blockade with amlodipine on LV mass,
RP, and ROS formation by monocytes, and that these
ffects were unrelated to the effects on BP. Both valsartan
nd amlodipine produced similar reductions in BP, but the
eductions in LVMI (primary outcome) and inflammatory
arkers such as ROS formation by monocytes and CRP
secondary outcome) were significantly greater with valsar-
an treatment (Table 3). There were significant correlations
t baseline between LVMI and ROS formation by mono-
ytes and between LVMI and CRP, as well as between
ecreases in the levels of these substances and regression of
VMI.
ffect of valsartan on monocyte oxidative stress and LV
ass. In the present study, we found that valsartan inhib-
ted ROS formation by monocytes. It has been previously
eported that ATII receptors are expressed in monocytes
nd that ATII increases ROS formation by monocytes (21).
ocally produced ATII might be involved in this increase
5,6). However, in the present study, we can only conclude
hat endogenous ATII may increase ROS formation by
onocytes.
The precise mechanism of ROS formation by monocytes
n conjunction with cardiomyocytes and LV mass alteration
emains to be elucidated. However, a multiple regression
nalysis indicated that there is a significant correlation
etween ROS formation by monocytes and LV mass (Fig.
, Table 2). In the valsartan group, the reduction in LVMI
orrelated with the reduction in ROS formation by mono-
ytes (Fig. 4), which suggests that the ATII-induced ROS
ormation by monocytes may be one of the major causes of
ncreased LV mass in patients with essential hypertension,
part from the increases in LV mass usually attributed to
levated BP. Valsartan has been found to have an antioxi-
ative effect (22), and it has been reported that increased
OS formation by monocytes increases cytokine produc-
ion, including IL-6 (13), which may cause myocardial
ypertrophy (14). Hence, reduced ROS formation by
onocytes with valsartan treatment may result in reduced
L-6 production and a corresponding decrease in LVH. In
act, it has been reported that IL-6 production is decreased
y valsartan (23).
ffect of valsartan on CRP and LV mass. The most
onspicuous differences between the two therapies in the
resent study were their effects on CRP levels. The CRP
eduction with valsartan treatment was significantly greater
han that with amlodipine (Table 3). We also observed that
he decrease in CRP in the valsartan group significantly
orrelated to the decrease in LVMI (Fig. 4). C-reactive
rotein has a direct modulatory effect on monocytes, which
romote IL-6 release (13) and may cause cardiac hypertro-
hy (14). Thus, ATII may interact with CRP, or mono-
ytes, and thus cause hypertrophy.It is interesting to note that studies with the ARBs
osartan and candesartan in patients with coronary artery
isease recently reported no effects on CRP levels from
reatment (24,25). Whether this is due to differences in
tudy design or differences between the ARBs remains to be
stablished. However, it should be pointed out that some
atients in the present study had severe LVH. In such
atients, the cardiac renin-angiotensin system may be en-
anced (26), which may exacerbate the inflammatory re-
ponse, including CRP.
tudy limitations. A limitation of the present study that
ay be considered significant is a possible bias due to
atient selection. Some patients in the present study had
evere LVH. This may call into question the applicability of
he results to other patient populations.
onclusions. The ARB valsartan seems to have effects on
RP, ROS formation by monocytes, and LVMI, unrelated
o a reduction in BP. There were also significant correla-
ions at baseline between LVMI and ROS formation by
onocytes and between LVMI and CRP, as well as
etween decreases in the levels of these substances and
egression of LVMI, suggesting the possible involvement of
nflammatory response such as ROS formation by mono-
ytes and CRP in an ATII-mediated increase in LV mass in
ypertensive patients.
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